Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from The United Laboratories International Holdings ( (HK:3933) ) is now available.
The United Laboratories International Holdings Limited announced its interim financial results for the six months ending June 30, 2025, reporting a 4.8% increase in revenue to RMB 7.52 billion compared to the same period in 2024. The company also saw significant growth in profitability, with EBITDA rising by 23.3% and profit attributable to owners increasing by 27%, reflecting strong operational performance and effective cost management.
The most recent analyst rating on (HK:3933) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a pharmaceutical company incorporated in the Cayman Islands. It focuses on the production and sale of antibiotics and other pharmaceutical products, serving the healthcare industry.
Average Trading Volume: 17,533,933
Technical Sentiment Signal: Buy
Current Market Cap: HK$32.4B
Find detailed analytics on 3933 stock on TipRanks’ Stock Analysis page.